|
|
Volumn 16, Issue 3, 2010, Pages 315-320
|
|
Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2'-FLUORO-5-METHYLARABINOSYLURACIL;
ALANINE AMINOTRANSFERASE;
ANTIVIRUS AGENT;
CLEVUDINE;
DRUG DERIVATIVE;
HEPATITIS B(E) ANTIGEN;
LAMIVUDINE;
URACIL ARABINOSIDE;
VIRUS DNA;
ADULT;
ANTIVIRAL RESISTANCE;
ARTICLE;
BLOOD;
CLINICAL TRIAL;
COMPARATIVE STUDY;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG ADMINISTRATION;
FEMALE;
GENOTYPE;
HEPATITIS B;
HUMAN;
MALE;
MIDDLE AGED;
RANDOMIZED CONTROLLED TRIAL;
ADULT;
ALANINE TRANSAMINASE;
ANTIVIRAL AGENTS;
ARABINOFURANOSYLURACIL;
DNA, VIRAL;
DOUBLE-BLIND METHOD;
DRUG ADMINISTRATION SCHEDULE;
DRUG RESISTANCE, VIRAL;
FEMALE;
GENOTYPE;
HEPATITIS B E ANTIGENS;
HEPATITIS B, CHRONIC;
HUMANS;
LAMIVUDINE;
MALE;
MIDDLE AGED;
|
|
EID: 79959515292
PISSN: 1738222X
EISSN: None
Source Type: Journal
DOI: 10.3350/kjhep.2010.16.3.315 Document Type: Article |
|
Times cited : (13)
|
|
References (0)
|
